[Dolutegravir, Abacavir and Lamivudine (Triumeq®) in HIV infection]
González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001396
Original Title: Dolutegravir, abacavir y lamivudina (Triumeq®) en infección por VIH
Authors' recomendations: CONCLUSIONS High quality evidence shows that combined dolutegravir, abacavir and lamivudine at fixed doses proved to be superior to the standard of care with efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC) when assessing the rate of patients reaching an undetectable viral load (less than 50 copies/mL) at Week 48 (88% vs. 81%), and it shows a better adverse event profile and a lower AE-related treatment discontinuation rate. The Argentine Society of Infectology considers it as a treatment option. As it is expensive, in Argentina, Brazil and Colombia, as well as in other countries of the region, the use of Triumeq® is limited to those patients with contraindication for other first-line regimens (e.g., intolerance, resistance or drug interaction). For GPC guidelines and health sponsors from Australia, Canada, Europe and the United States, Triumeq® is the preferred option over EFV/TDF/FTC and other regimens, due to its high effectiveness and better tolerance.
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- HIV Infections
- Drug Therapy, Combination
- Anti-Retroviral Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.